Sanofi's New Chief Faces Uphill Battle to Revive Drug Pipeline and Manage U.S. Vaccine Sentiment
Belén Garijo, 65, who will take over as Sanofi's CEO in April, inherits a company grappling with a stalled development pipeline, heavy reliance on the asthma drug Dupixent for revenues, declining vaccine sales and a share price under pressure. Investors praise her operational rigor but point to a mixed R&D track record at Merck KGaA, where she has …